ArticleFrontiers in immunology2026
The potential role of antimetabolite in preventing allosensitization before kidney retransplantation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Retransplantation is becoming more common. Allosensitization represents an increasing issue, as it prolongs the time on the waiting list and worsens the outcome of a second transplant. The optimal maintenance immunosuppression (IS) after graft failure remains unclear. Methods: This is a retrospective single-center study including kidney retransplant recipients (KRTRs) who underwent a retransplantation in the University Hospital of Zurich between 2012 and 2023. We analyzed which factors and especially which kind of maintenance IS after graft failure could affect allosensitization. Results: In our cohort, 191/1,040 (16%) were retransplantations. Of the included KRTRs, 27/129 (20%) were living donations (LDs). The median waiting time for deceased donations (DDs) was 4 years. The burden of IS decreased from graft failure to retransplantation (triple IS 54 vs. 12%, Conclusion: The intake of antimetabolite at retransplantation showed a protective effect against allosensitization. Waiting time to retransplantation had only a weak correlation with allosensitization over the whole cPRA spectrum in this Swiss cohort study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.